<DOC>
	<DOCNO>NCT00584194</DOCNO>
	<brief_summary>This study design determine safety immunogenicity Rift Valley Fever ( RVF ) Vaccine</brief_summary>
	<brief_title>Safety Immunogenicity Study Rift Valley Fever Vaccine</brief_title>
	<detailed_description>Study Objectives : The objective two-part , primary immunization booster dose , study continue collect safety data Rift Valley Fever ( RVF ) Vaccine , Inactivated ( TSI-GSD 200 ) ; , continue collect immunogenicity data Rift Valley Fever ( RVF ) Vaccine , Inactivated ( TSI-GSD 200 ) analyze interim data determine whether 6-month dose indicate ; , provide potential protection personnel risk occupational exposure RVF virus collect data incidence occupational RVF infection ( subclinical clinical ) immunize personnel .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Coccidioidomycosis</mesh_term>
	<mesh_term>Coccidiosis</mesh_term>
	<mesh_term>Rift Valley Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Parts A &amp; B : At least 18 year old , active military duty , 17 year old , Females childbearing potential must agree urine pregnancy test within 48 hour receipt dose vaccine . The test result must negative . Females advise become pregnant 3 month primary series booster dose , must breastfeed , Subject must actively enrol SIP vaccinate USAMRIID otherwise authorize ( documentation ) DOD Subjects must risk exposure RVF virus , Subjects must uptodate ( within 1 year ) medical history , physical examination , laboratory test chart medically clear participation investigator . Examinations test may repeat within 1 year discretion enrol physician . Volunteer must sign date approve informed consent ( Volunteer Agreement Explanation Affidavit ) . Additional Inclusion Criteria Part B : • Completion primary series followup titer ( PRNT80 ) &lt; 1:40 current previous RVF IND 365 protocol . Exclusion Criteria Parts A &amp; B : Clinically significant abnormal lab result include evidence Hepatitis C , Hepatitis B carrier state , elevate liver function test . Personal history immunodeficiency current treatment immunosuppressive medication , discretion physician . Confirmed HIV infection . Any medical condition , discretion physician , may jeopardize safety volunteer . Any serious lifethreatening allergy component vaccine : formalin , human serum albumin , neomycin , streptomycin Administration vaccine within 28 day dose RVF vaccine . Any unresolved adverse event result previous immunization . Additional Exclusion Criteria Part B : • An adequate PRNT80 ( ≥ 1:40 ) completion primary series .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemorrhagic Fever , Viral Infections , Neurologic diseases , Arbovirus Infections , RVF</keyword>
</DOC>